FilingReader Intelligence

Everest Medicines raises HK$1.57bn through share placing

July 24, 2025 at 11:49 PM UTCBy FilingReader AI

Everest Medicines will raise gross proceeds of approximately HK$1.57bn through placing 22.6m existing shares and a concurrent top-up subscription at HK$69.70 per share, representing a 10.12% discount to the previous closing price.

Net proceeds of HK$1.55bn will fund global R&D (50%), commercialization efforts (40%), and working capital (10%).

This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com

News Alerts

Get instant email alerts when Everest Medicines publishes news

Free account required • Unsubscribe anytime

Filing Activity Timeline

View Complete Filing History →